
News|Videos|May 4, 2026
ARVO 2026: Is Grok a valuable tool for patients?
Author(s)Martin David Harp
The poster looked into the LLM's potential for biases in gender and race when it came to its knowledge of retinitis pigmentosa.
Advertisement
Renee Long, from the University of California San Diego, took some time to discuss her poster on the viability of Grok as a tool for patients in ophthalmology. Long looked into the LLM's potential for biases in gender and race when it came to its knowledge of retinitis pigmentosa.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
NCX 470 gains positive regulatory feedback in China ahead of US NDA submission
2
DSLT for glaucoma and ocular hypertension: Real-world outcomes in 218 eyes
3
FDA accepts Outlook Therapeutics' resubmitted BLA for ONS-5010 (LYTENAVA)
4
Tinlarebant NDA submission completed for Stargardt disease type 1, targeting first approved therapy
5





















